Your session is about to expire
← Back to Search
Combination Immunotherapies for Non-Small Cell Lung Cancer (ARC-7 Trial)
ARC-7 Trial Summary
This trial will study the safety and effectiveness of two different immunotherapy treatments for people with non-small cell lung cancer.
ARC-7 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowARC-7 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ARC-7 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had active cancer in the last 2 years, except for certain treated and cured types.I have not received any live vaccines in the last 28 days.I am taking high doses of steroids or medications that suppress my immune system.You must have at least one detectable and measurable abnormality according to specific medical guidelines.I haven't needed systemic treatment for an autoimmune disease in the last 2 years, except for vitiligo or childhood asthma.My lung cancer is untreated, spreads, has high PD-L1, and no EGFR or ALK changes.I can take oral medications without issues like swallowing difficulty or severe nausea.I have not had major surgery or serious injury in the last 28 days.I am 18 years old or older.I am fully active or restricted in physically strenuous activity but can do light work.My organs and bone marrow are working well.You have tested positive for Hepatitis B, Hepatitis C, or HIV.
- Group 1: Arm 1 (zimberelimab monotherapy)
- Group 2: Arm 2 (domvanalimab and zimberelimab combination therapy)
- Group 3: Arm 3 (domvanalimab, etrumadenant, and zimberelimab combination therapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the potential side effects of Zimberelimab?
"Zimberelimab's safety is based on Phase 2 trial data, which means that while there is some evidence of its safety, there is no guarantee of its efficacy. Therefore, it received a score of 2."
Can more people still join this clinical trial?
"No, this specific trial is not actively seeking patients at this time. Although, it should be noted that the last update to this study was on November 8th, 2022 and there are currently 2239 other medical trials recruiting volunteers."
Is this trial limited to a specific region or country?
"Presently, this study is taking place in 50 different clinics. These are situated in cities such as Bethesda, Greenville and New Orleans - amongst others. If you're considering participating, it would be most convenient to choose a location near to you to avoid extensive travel."
What are the goals of this trial?
"The primary outcome metric for this study, which will be followed over the next 3 to 5 years, is progression-free survival. Additionally, the secondary outcomes include pharmacokinetics of domvanalimab and overall survival. Furthermore, researchers will also evaluate the number of patients that experience treatment emergent adverse events."
Share this study with friends
Copy Link
Messenger